Jon Kaufman, PhD
Chief Executive Officer
Dr. Kaufman co-founded Lipella and has served as CEO since the company’s 2005 inception. In his career, he helped co-found Knopp Biosciences, which signed a deal with Biogen Idec for $345M (2010), and served as CFO of Semprus Biosciences, which sold to Teleflex for $80M (2012).

Dr. Kaufman has been Lipella’s principal investigator for federal grant programs to fund its pre-clinical and clinical programs. He also manages operations, as well as relationships with existing investors and corporate partners.

Dr. Kaufman earned his PhD in Biophysics from the University of Pennsylvania School of Medicine and his MBA in Finance from the Wharton School.
Michael Chancellor, MD
Chief Medical Officer
As an internationally recognized expert in the treatment of urinary bladder dysfunction, Dr. Michael Chancellor is a key opinion leader in the field. He has conducted over 75 clinical trials and has consulted with numerous biotech companies developing urology products. His client list includes Pfizer, Merck, J&J, Lilly, AstraZeneca, Allergan, Astellas, P&G, and Indevus. He has extensive experience in clinical trial design and FDA communications.

In 2005, Dr. Chancellor co-founded Lipella and has served as the company's CMO since then. In 2008, he joined Lipella full-time, while maintaining a part-time academic appointment at the William Beaumont Medical Center.

A board-certified urologist, Dr. Chancellor earned his MD from the University of Michigan.
Michele Gruber
Director of Operations
Michelle Gruber is responsible for Lipella’s sterile GMP manufacturing facility and analytical services as well as Lipella’s outsourcing of GLP distribution and toxicology studies that support Lipella’s FDA IND filings. Ms. Gruber earned her BS in Chemistry from Carnegie Mellon University.
Jeannine Ramsey
Clinical Coordinator
Jeannine serves as a liaison between Lipella and our clinical research sites within academic and community medical institutions. For nearly a decade Jeannine has worked in the clinical research field as a monitor, an auditor, and project management. Her strong working knowledge of the laws and regulations governing clinical research trials in the US and overseas has contributed to numerous successful clinical trials. Jeannine has served as a registered nurse in obstetrics, neonatal intensive care, the operating room, pediatric home health care, and as a school nurse. Additionally, she held the position of quality clinical analyst. Jeannine received her Bachelor of Science Degree in Nursing from Ashland University.
Kirk French, CPA
Chief Financial Officer
Kirk French is responsible for overseeing corporate financial control, cash and treasury management, tax reporting, human resources, compliance with federal audit requirements, ongoing in-license and out-license royalty arrangements, vendor relationships and financial relationships with subcontractors of federal awards. Mr. French is a CPA and earned his MBA from the University of Idaho.
Dave McClellan
Senior Advisor
Dave McClellan joined the Lipella management team in June 2013. His responsibilities include corporate partnerships, strategic planning, business development and investment banking relations.

During his tenure at Boston Scientific, Mr. McClellan moved through the ranks from various sales and marketing positions to lead the company’s Medi-tech Division, which included the Peripheral Interventions, Vascular Surgery and Oncology businesses. He was also instrumental in building Boston Scientific’s Peripheral Interventions and Vascular Surgery units. In 2003, Mr. McClellan created the company’s Oncology and Vascular Access businesses. Later, he was the architect for divesting and capturing value for Boston Scientific’s Cardiology and Oncology product lines. Mr. McClellan was appointed President of Navilyst Medical and successfully transitioned the company from Boston Scientific into a leading medical device organization.

Mr. McClellan was appointed to Senior Advisor for Semprus BioSciences and helped engineer its strategic vision and eventual sale to Teleflex Medical in 2012.

Mr. McClellan was a former board member for Beth Israel Deaconess Hospital-Needham and RFK Children’s Action Corp. He is a board member for HealthStar Communications, Inc.